Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Effect of gene environment interactions on lung function and cardiovascular disease in COPD

Authors Hackett TL, Stefanowicz D, Aminuddin F, Sin DD, Connett JE, Anthonisen NR, Paré PD, Sandford AJ

Published 10 May 2011 Volume 2011:6 Pages 277—287

DOI https://doi.org/10.2147/COPD.S18279

Review by Single-blind

Peer reviewer comments 3

Tillie-Louise Hackett1,2,*, Dorota Stefanowicz1,*, Farzian Aminuddin1, Don D Sin1, John E Connett3, Nicholas R Anthonisen4, Peter D Paré1, Andrew J Sandford1
1
University of British Columbia, James Hogg Research Laboratories, St Paul's Hospital, Division of Respirology, Department of Medicine, 2Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, BC, Canada; 3School of Public Health, University of Minnesota, Minneapolis, MN, USA; 4Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
*These authors contributed equally to this work

Background: The objective of this study was to determine if gene-environment interactions between cigarette smoking and interleukin-6 (IL6), interferon-γ (IFNG), interleukin-1β (IL1B), or interleukin-1 receptor antagonist (IL1RN) single nucleotide polymorphisms are associated with lung function decline and cardiovascular disease in chronic obstructive pulmonary disease (COPD).
Methods: Single nucleotide polymorphisms (SNPs) in IL6, IFNG, IL1B, and IL1RN were genotyped in the Lung Health Study and correlated with rate of decline of forced expiratory volume in 1 second (FEV1) over 5 years, baseline FEV1, serum protein levels, cardiovascular disease, and interactions with smoking.
Results: The IL6 rs2069825 single nucleotide polymorphism was associated with the rate of decline of prebronchodilator FEV1 (P = 0.049), and was found to have a significant interaction (P = 0.004) with mean number of cigarettes smoked per day. There was also a significant interaction of IFNG rs2069727 with smoking on prebronchodilator (P = 0.008) and postbronchodilator (P = 0.01) FEV1. The IL6 polymorphism was also associated with cardiovascular disease in heterozygous individuals (P = 0.044), and was found to have a significant interaction with smoking (P = 0.024). None of the genetic variants were associated with their respective serum protein levels.
Conclusion: The results suggest interactions of IL6 rs2069825 and IFNG rs2069727 single nucleotide polymorphisms with cigarette smoking on measures of lung function. The IL6 rs2069825 single nucleotide polymorphism also interacted with smoking to affect the risk of cardiovascular disease in COPD patients.

Keywords: gene-environment interactions, interleukin-6, forced expiratory volume in one second, cardiovascular disease, chronic obstructive pulmonary disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects

Kapella MC, Herdegen JJ, Perlis ML, Shaver JL, Larson JL, Law JA, Carley DW

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:625-635

Published Date: 24 November 2011

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:73-81

Published Date: 13 January 2011